Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Bigger, More Expensive Healthcare Practices Not Necessarily Better

Ronnie Cohen  |  May 15, 2017

The authors conclude that the weak association they found between price and the quality of care calls into question providers’ claims that their higher prices signal higher-value care.

The study found that high-price practices were much larger in size than low-price practices, suggesting that “larger provider groups with market power are able to command substantially higher prices without having to offer markedly better care than smaller practices,” the authors say.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“There’s a widespread conception that bigger is better, and all of this leads to better outcomes for patients,” says senior author Dr. J. Michael McWilliams, a professor of healthcare policy at Harvard Medical School.

“We know it leads to higher prices. What has been less clear is whether it has led to higher quality,” he tells Reuters Health. “And we’ve convincingly shown that large-scale consolidation does not benefit patients.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Large practices, with on average 155 clinicians, charged 20% more on average for office visits than small ones, which had an average of 11 clinicians, the study found. Like patients in high-priced practices, patients in large practices reported shorter time spent in waiting rooms before seeing doctors, better care coordination and management and that they were more likely to receive pneumonia and flu vaccines than patients in small practices.

But patients perceived their care similarly in small and large physician practices, except that overall ratings of care tended to be worse in large practices than in small ones.

“Small practices in many ways do as well as large practices,” Gaynor says. “Bigger is not necessarily better. Sometimes bigger is worse.”


Reference

  1. Roberts ET, Mehrotra A, McWilliams JM. High-price and low-price physician practices do not differ significantly on care quality or efficiency. Health Aff (Millwood). 2017 May 1;36(5):855-864. doi: 10.1377/hlthaff.2016.1266.

Page: 1 2 | Single Page
Share: 

Filed under:Practice Support Tagged with:alternative therapiescostsHealth carepatient care

Related Articles

    Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

    June 14, 2017

    While members of Congress debate healthcare legislation, rheumatologists say many of their patients struggle to afford everything from generic drugs to insurance copayments for physical therapy. “It’s a mess. The cost of prescriptions and the rationale for those rising costs in the U.S. right now—it’s just a mess,” says James R. O’Dell, MD, Stokes-Shackleford Professor of…

    The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

    June 15, 2017

    Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

    Major Drugmakers Push Back in U.S. Price Debate

    January 15, 2016

    SAN FRANCISCO (Reuters)—With a backlash brewing over the price of medicines in the U.S., drugmakers are pushing back with a new message: Most people don’t pay retail. Top executives from Eli Lilly and Co, Merck & Co and Biogen Inc. said in interviews with Reuters this week that the media focus on retail, or “list…

    U.S. Supreme Court Upholds Obamacare Insurance Subsidies

    June 25, 2015

    WASHINGTON (Reuters)—The U.S. Supreme Court preserved President Barack Obama’s signature healthcare law on Thursday, upholding crucial tax subsidies while turning aside a conservative legal challenge that could have doomed the law. “After more than 50 votes in Congress to repeal or weaken this law, after a presidential election based in part on preserving or repealing…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences